Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Support for HR 1862, the Regenerative Medicine Promotion Act.
Qualifying Therapeutic Discovery Project Tax Credit Extension Act of 2011
Support Medical Device Excise Tax Repeal Efforts Support HR 1988, the Theraputic Tax Credit Extension Act of 2011 Support HR 2632, the Life Science Jobs and Investment Act
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
Support for HR 1862, the Regenerative Medicine Promotion Act.
Support Medical Device Excise Tax Repeal Efforts Support HR 1988, the Theraputic Tax Credit Extension Act of 2011 Support HR 2632, the Life Science Jobs and Investment Act
Source: Senate LDA
Discussed concerns over the impact medical device and drug FDA regulation has on innovation, jobs, patients and the economy. Addressed changes to 510K process and concerns over an increasingly unpredictable regulatory system. Adressed concerns over lack of effective communication between FDA and industry, as well as administrative issues such as concerns over the FDA's access to training and education on the newest technologies. Addressed concerns over proposed new limitations on the scope of RUO and IUO products. Discussed concern that the proposed restrictions would negitively impact the practice of developing and validating clinical tests using RUO and IUO components, and would significantly change the way manufacturers can promote and sell their products, and in so doing irreparably harm innovation in this area. Addressed BIOCOM's support for a 12 year data exclusivity period for biologic products and our strong opposition to any proposed reduction to the 12 year data exclusivity period. Addressed opposition to the IOM's recommendation to dismantle the FDA 510K process. Support HR 2182, The Generating Antibiotic Incentives Now ("GAIN") Act.
Support Medical Device Excise Tax Repeal Efforts Support HR 1988, the Theraputic Tax Credit Extension Act of 2011 Support HR 2632, the Life Science Jobs and Investment Act
Addressed opposition over the Independent Payment Advisory Board ("IPAB"). Expressed concern over the IPAB which is an unelected body that could institute broad changes to Medicare with no Congressional input or oversight. Opposed proposed cuts to Medicare Part D, which provides seniors with a drug benefit, and Part B, which provides oncology products for administration in physicians offices.
Discussed concerns over the impact medical device and drug FDA regulation has on innovation, jobs, patients and the economy. Addressed changes to 510K process and concerns over an increasingly unpredictable regulatory system. Adressed concerns over lack of effective communication between FDA and industry, as well as administrative issues such as concerns over the FDA's access to training and education on the newest technologies. Addressed concerns over proposed new limitations on the scope of RUO and IUO products. Discussed concern that the proposed restrictions would negitively impact the practice of developing and validating clinical tests using RUO and IUO components, and would significantly change the way manufacturers can promote and sell their products, and in so doing irreparably harm innovation in this area. Addressed BIOCOM's support for a 12 year data exclusivity period for biologic products and our strong opposition to any proposed reduction to the 12 year data exclusivity period. Addressed opposition to the IOM's recommendation to dismantle the FDA 510K process. Support HR 2182, The Generating Antibiotic Incentives Now ("GAIN") Act.
Address issues related to HR/1249 and S 23, the patent reform legislation, including support for fee retention, and putting an end to qui tam complaints for alleged false markings.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ENG, FIN, FOO, FUE, HCR, HOM, MAN, MED, MMM, PHA, SCI, SMB, TAX, TRD, VET, WAS, FDA Reform, 510(k), R&D Tax Credits, SBIR/STTR, FDA Funding, NIH Funding, CAN ACT, FOB's Importation, Taxation/IRS, Veterans, Waste, Trade, Pharmacy issues
ENG, FIN, FOO, FUE, HCR, HOM, MAN, MED, MMM, PHA, SCI, SMB, TAX, TRD, VET, WAS, FDA Reform, 510(k), R&D Tax Credits, SBIR/STTR, FDA Funding, NIH Funding, CAN ACT, FOB's Importation, Taxation/IRS, Veterans, Waste, Trade, Pharmacy issues
ENG, FIN, FOO, FUE, HCR, HOM, MAN, MED, MMM, PHA, SCI, SMB, TAX, TRD, VET, WAS, FDA Reform, 510(k), R&D Tax Credits, SBIR/STTR, FDA Funding, NIH Funding, CAN ACT, FOB's Importation, Taxation/IRS, Veterans, Waste, Trade, Pharmacy issues
ENG, FIN, FOO, FUE, HCR, HOM, MAN, MED, MMM, PHA, SCI, SMB, TAX, TRD, VET, WAS, FDA Reform, 510(k), R&D Tax Credits, SBIR/STTR, FDA Funding, NIH Funding, CAN ACT, FOB's Importation, Taxation/IRS, Veterans, Waste, Trade, Pharmacy issues
ENG, FIN, FOO, FUE, HCR, HOM, MAN, MED, MMM, PHA, SCI, SMB, TAX, TRD, VET, WAS, FDA Reform, 510(k), R&D Tax Credits, SBIR/STTR, FDA Funding, NIH Funding, CAN ACT, FOB's Importation, Taxation/IRS, Veterans, Waste, Trade, Pharmacy issues
ENG, FIN, FOO, FUE, HCR, HOM, MAN, MED, MMM, PHA, SCI, SMB, TAX, TRD, VET, WAS, FDA Reform, 510(k), R&D Tax Credits, SBIR/STTR, FDA Funding, NIH Funding, CAN ACT, FOB's Importation, Taxation/IRS, Veterans, Waste, Trade, Pharmacy issues
ENG, FIN, FOO, FUE, HCR, HOM, MAN, MED, MMM, PHA, SCI, SMB, TAX, TRD, VET, WAS, FDA Reform, 510(k), R&D Tax Credits, SBIR/STTR, FDA Funding, NIH Funding, CAN ACT, FOB's Importation, Taxation/IRS, Veterans, Waste, Trade, Pharmacy issues
ENG, FIN, FOO, FUE, HCR, HOM, MAN, MED, MMM, PHA, SCI, SMB, TAX, TRD, VET, WAS, FDA Reform, 510(k), R&D Tax Credits, SBIR/STTR, FDA Funding, NIH Funding, CAN ACT, FOB's Importation, Taxation/IRS, Veterans, Waste, Trade, Pharmacy issues
ENG, FIN, FOO, FUE, HCR, HOM, MAN, MED, MMM, PHA, SCI, SMB, TAX, TRD, VET, WAS, FDA Reform, 510(k), R&D Tax Credits, SBIR/STTR, FDA Funding, NIH Funding, CAN ACT, FOB's Importation, Taxation/IRS, Veterans, Waste, Trade, Pharmacy issues